Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 13/20 | 0.67 |
| ▸ | KIF11 | P52732 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 6/20 | 0.65 |
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | RAD52 | P43351 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.65 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL560221 | 0.98 | KIF11 (0.68) | FPR2KIF11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4274255 | 0.89 | FPR2 (0.61) | FPR2KIF11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL1070098 | 0.88 | FPR2 (0.62) | FPR2KIF11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL560413 | 0.87 | KIF11 (0.71) | FPR2KIF11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL26000676 | 0.87 | FPR2 (0.68) | FPR2KIF11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL30057046 | 0.87 | FPR2 (0.68) | FPR2KIF11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL10168899 | 0.87 | KIF11 (0.73) | FPR2KIF11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL560511 | 0.86 | KIF11 (0.70) | FPR2KIF11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL12431848 | 0.86 | FPR2 (0.60) | FPR2KIF11LMNAMAPTSMN1; SMN2 | |
| SCHEMBL12715946 | 0.86 | FPR2 (0.60) | FPR2KIF11LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | CORRIDOR PHARMACEUTICALS, INC. | 2012-02-09 | — | — | US | disclosed |
| US-7981885-B2 | N-[3-substituted piperazino] alkylphenothiazines; antiproliferative agents, apoptotic agents; 5-HT receptor antagonists | IMMUNE CONTROL INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7923445-B2 | 10-{3-[4-(2-Amino)ethylpiperazinyl]propyl}2-trifluoromethylphenothiazine and analogues and derivatives; antiproliferative agents; serotonin receptor antagonists; apoptosis in activated lymphocytes, including T, B, and and mylenoma cells; asthma; antiarthritic agents; rheumatic diseeases | IMMUNE CONTROL, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2061788-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES RELATED TO ACTIVATED LYMPHOCYTES | Immune Control, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | IMMUNE CONTROL, INC. (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2008027521-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES RELATED TO ACTIVATED LYMPHOCYTES | IMMUNE CONTROL, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132697-A1 | Novel compositions for treatment of diseases related to activated lymphocytes | NFATC1, CD4, TPH1 | FPR2 43/4885KIF11 4417/4885LMNA 1395/4885 |
| US-20120035161-A1 | Novel Compositions and Methods of Treating Diseases Using the Same | NFATC1, BAX, BCL2 | FPR2 153/4885KIF11 3636/4885LMNA 301/4885 |
| US-20080125415-A1 | Novel methods for treatment of diseases related to activated lymphocytes | HTR5A, TPH1, TPH2 | FPR2 47/4885KIF11 4402/4885LMNA 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.